To be more specific, AML patients with high expression of RAB39B exhibited a significant association with adverse cytogenetic risk (P < 0.001) and specific FAB classifications (P < 0.001), excluding the M3 type due to its distinct treatment regimen involving ATRA. The gene discussed is RAB39B; the disease is acute myeloid leukemia.